https://www.selleckchem.com/JAK.html
5%) of the patients, and in 13 of 50 (26%) exposures. No clinical, genetic, demographic, or therapeutic feature could predict which FMF patient would respond favorably to TNF-blocker therapy. This study suggests that TNF-blockers may be beneficial for a small proportion of colchicine-resistant FMF patients. This study suggests that TNF-blockers may be beneficial for a small proportion of colchicine-resistant FMF patients.Depression constitutes the most frequent comorbid condition associated with rheumatoid arthritis (RA), with prevalence rates rangi